Download referencia bibliográfica - Seminario en Medicina y Salud

C-64 “GENÉRICOS INTERCAMBIABLES”
3
REFERENCIA BIBLIOGRÁFICA
1. Abraham J, Sheppard J, et al. Rethinking transparency and accountability in
medicines regulation in the Unites Kingdom. BMJ 1999;318(2):46-7.
2. Ferriman A. Supply of generic drugs still unreliable. BMJ 2000;320:1624.
3. Beeley N, Berger A. A revolution in drug discovery. BMJ 2000;321:581-2.
4. Walton R. Computer support for determining drug dose: systemic review and metaanalysis. BMJ 1999;318(7198):1584. Resumen.
5. Dieperink ME, Drogemuller L. Industry-Sponsored Grand Rounds and Prescribing
Behavior. JAMA 2001;285(11):1443-4.
6. Beecham L. MPs say the market for generic drugs is “ripe for manipulation”. BMJ
2000;320(7226):7.
7. Bird D. Improvement in prescribing can be measured only over time.
2001;322(7281):302.
BMJ
8. Jones J. Government orders inquiry as price of generic drugs soars. BMJ
1999;319(7218):1151.
9. Vallee JP Generic drugs and the rights of substitution.
1999;28(10):535-8.
Presse Medicale
10. Banahan B, Kolassa EM. A Physician Survey on Generic Drugs and Substitution of
Critical Dose Medications. Arch Intern Med 1997;157(18);2080-8.
11. Meyer GF. Transplant
1999;31(3A):10S-12S.
Proceedings.
NIH/NLM
Medline,
HealthSTAR
12. Porro GB, Lazzaroni M, et al. Omeprazole and sucralfate in the treatment of
NSAID-induced gastric and duodenal ulcer.
Alimentary Pharmacology &
Therapeutics 1998;12(4):355-60.
13. Soo S, Moayyedi P, et al. Pharmacological interventions for non-ulcer dyspepsia.
Cochrane Database of Systematic Reviews 2001;Issue 2.
14. Merck Sharp & Dohme de México. Maduretic (Hidroclorotiazida y Clorhidrato de
Amilorida, MSD). PLMlatina.com
C-64 “GENÉRICOS INTERCAMBIABLES”
4
REFERENCIA BIBLIOGRÁFICA
15. Loperamide plus simethicone reduced the duration and symptoms of acute diarrhea.
ACP Journal Club 1999;131:66.
16. Review: Smooth-muscle relaxants treat abdominal pain and loperamide reduces
diarrhea in the irritable bowel syndrome. ACP Journal Club 2001;134(1):18.
17. Domino KB, Anderson EA, et al. Comparative efficacy and safety of ondansetron,
droperidolm and metoclopramide for preventing postoperative nausea and vomiting:
a meta-analysis. Anesthesia and Analgesia 1999;88(6):1370-9.
18. Peterson W, Cook D. Antisecretory Therapy for Bleeding Peptic Ulcer. American
Medical Association 1998;280(10):877-8.
19. Lysine acetylsalicylate combined with metoclopramide was as effective as
sumatriptan for migraine. ACP Journal Club 1996;124;36.
20. Misoprostol reduced serious NSAID-induced gastrointestinal complications in
rheumatoid arthritis. ACP Journal Club 1996;24:38.
21. Omeprazole healed ulcers and maintained remission better than ranitidine. ACP
Journal Club 1998;129:9.
22. Omeprazole maintained remission from ulcers better than misoprostol.
Journal Club 1998;129:8.
ACP
23. Yeomans ND, Tulassay Z, et al. A comparison of omeprazole with ranitidine for
ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression
Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment
(ASTRONAUT) Study Group. New England Journal of Medicine
1998;338(11):719-26.
24. Hawjey CJ, Karrasch JA, et al. Omeprazole compared with misoprostol for ulcers
associated with nonsteroidal anti-inflammatory drugs.
Omeprazole versus
Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.
New England Journal of Medicine 1998;338(11):727-34.
25. Omeprazole was better than cisapride or placebo for controlling heartburn at 4 and 8
weeks. ACP Journal Club 2000;132(2):64.
26. Omeprazole did not reduce mortality, rebleeding, surgery, or transfusion required in
acute upper gastrointestinal bleeding. ACP Journal Club 1992;117:16.
C-64 “GENÉRICOS INTERCAMBIABLES”
5
REFERENCIA BIBLIOGRÁFICA
27. Intermittent treatment with ranitidine or omeprazole for 1 year was effective for
gastro-oesophageal reflux disease. Evidence-Based Medicine 1999;4:119.
28. Meta-analysis: Misoprostol reduces NSAID-induced gastrointestinal mucosal
injury. ACP Journal Club 1997;126:36.
29. Misoprostol was most cost-effective if risk for NSAID-related GI events was high.
ACP Journal Club 1998;129:25.
30. Omeprazole maintained remission from ulcers better than misoprostol. ACP Journal
Club 1998;129:8.
31. It is unclear whether misoprostol is cost-effective in preventing NSAID gastropathy.
ACP Journal Club 1995;122:53.
32. It is unclear whether misoprostol is cost-effective in preventing NSAID gastropathy.
ACP Journal Club 1995;122:53.
33. Bernard B, Grange JD, et al. Antibiotic prophylaxis for the prevention of bacterial
infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.
Hepatology 1999;29(6):1655-61.
34. Soareas-Weiser K, Brezis M, et al. Antibiotic prophylaxis for bacterial infections in
cirrhotics with gastrointestinal bleeding. The Cochrane Library 2001;(Issue2).
35. Sutherland LR, May GR, et al. Sulfasalazine revisited: a meta-analysis of 5aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal
Medicine 1993;118(7):540-9.
36. Dite P, Precechtelova M, et al. Principles of conservative treatment in chronic
pancreatitis. Vnitrni Lekarstvi 2000;46(3):184-6.
37. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134-8.
38. Mehl B, Santell J. Projecting future drug expenditures-2000. Am J Health Syst
Pharm 2000;57(2):129-38.
39. Laxatives and fibre therapies improve bowel movement frequency in adults with
chronic constipation. Evidence-Based Medicine 1997;2:147.
C-64 “GENÉRICOS INTERCAMBIABLES”
6
REFERENCIA BIBLIOGRÁFICA
40. Findlay SD, Direct-to-consumer promotion of prescription drugs. Economic
implications for patients, payers and providers.
Pharmacoeconomics
2001;19(2):109-19.
41. Mitchell E, Sullivan F. A descriptive feast but an evaluative famine: systemic
review of published articles on primary care computing during 1980-97. BMJ
2001; 322(7281):279-82.
42. Banaham BF, Kolassa EM. A physician survey on generic drugs and substitution of
critical dose medications. Archives of Internal Medicine 1997; 157(18):2080-8.
43. Novakovic J. Validation of a high-performance thin-layer chromatographic method
for trace analysis for some generic drugs affecting gastrointestinal function. Journal
of AOAC International 2000; 83(6):1507-16.
44. Ernst ME, Kelly MW, et al. Prescription medication costs: a study of physician
familiarity. Archives of Family Medicine 2000; 9(10):1002-7.
45. Levy R. Utilization of interchangeable generic drugs in Mexico. Salud Pública de
México 1999; 41(5):435.
46. Lifshitz A. Generic drugs and medical education. Gaceta Médica de México 2000;
136(5):535.
47. Rodríguez-Carranza R, Vidrio H, et al. Generic drugs and medical education.
Gaceta Médica de México 2000; 136(4):341-51.
48. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings
for generic prescription drugs. Journal of the American Pharmaceutical Association
2000; 40(3):378-83.
49. Beecham L. MPs say the market for generic drugs is “ripe for manipulation”. BMJ
2000; 320(7226):7.
50. Mehl B, Santell JP. Projecting future drug expenditures 2000. American Journal of
Health-System Pharmacy 2000; 57(2):129-38.
51. Jones J, Government orders inquiry as price of generic drugs soars. BMJ 1999;
319(7218):1151.
52. Siegel-Itzkovich J. Israel introduces generic drugs scheme.
319(7210):592.
BMJ 1999;
C-64 “GENÉRICOS INTERCAMBIABLES”
7
REFERENCIA BIBLIOGRÁFICA
53. McGilveray IJ, Gallicano K. Generic drugs: the Canadian perspective.
Transplantation Proceedings 1999; 31(3A Suppl):16S-18S.
54. Meyer GF. History and regulatory issues of generic drugs.
Proceedings 1999; 31(3A Suppl):10S-12S.
Transplantation
55. Palma-Aguirre JA. Generic drugs, bioavailability, and bioequivalence.
Medica de Mexico 1998; 134(4):491-4.
Gaceta
56. WHO medicines strategy. 2001.
57. Objectives of the Policy, Access, and Rational drug use (PAR) team.
58. The Rationale. Access, Quality and Rational Use of Medicines and Essential Drugs.
59. Essential Drugs. WHO Model list (revised December 1999).
60. Captopril. Bioequivalence study of apo-capto 100 mg and Capoten 100 mg.
61. Prescripción basada en evidencia.
62. Zinc.
63. Zidovudina
64. Paracetamol.
65. Aciclovir.
66. Ranitidina.
67. Proposed Revised Drug Strategy Resolution.
68. US compulsory licensing proposal for medicines.
69. USA compulsory licensing proposal for medicines.
70. Brazilian proposed resolutions to World Health Assembly.
71. Revised drug strategy. World Health Organization.2001.
C-64 “GENÉRICOS INTERCAMBIABLES”
8
REFERENCIA BIBLIOGRÁFICA
72. Objectives of the Policy, Access, and Rational drug use (PAR) team. Essential
Drugs and Medicine Policy.
73. Essential Drugs. WHO Model List (revised December 1999).
74. Los Alcaloides de opio (001918).
75. Clindamycin Phosphate. (003129).
76. Butilhioscina.
77. Escopolamina.
78. Dicyclomine Hydrochloride (001048).
79. Neomycin Sulfate (001868).
80. Butilhioscina y Metamizol.
81. Cisaprida
82. Acetaminophen; Butalbital (000020)
83. Lista de Genéricos SSA-2001 (Total 129)
84. Suipharma (Vademécum)
85. Listado de Artículos (Búsqueda)
86. Listado de Artículos (Búsqueda)
87. Propoxyphene Hydrochloride. Mosby’s Drug consult 2002, Inc.
88. Quinidine Sulfate. Mosby’s Drug consult 2002, Inc.
89. Pentoxifylline. Mosby’s Drug consult 2002, Inc.
90. Propafenone Hydrochloride. Mosby’s Drug consult 2002, Inc.
91. Clinical Studies. MD Consult. Isordil Sublingual Tablets
92. Warfarin Sodiuim. Mosby’s Drug consult 2002, Inc.
C-64 “GENÉRICOS INTERCAMBIABLES”
9
REFERENCIA BIBLIOGRÁFICA
93. Norepinephrine Bitartrate. Mosby’s Drug consult 2002, Inc.
94. Tramadol. Mosby’s Drug consult 2002, Inc.
95. Neostigmine Methylsufate. Mosby’s Drug consult 2002, Inc.
96. Naloxone Hydrochloride. Mosby’s Drug consult 2002, Inc.
97. Methylene Blue. Mosby’s Drug consult 2002, Inc.
98. Flumazenil. Mosby’s Drug consult 2002, Inc.
99. Antidotal Flumazenil use the protamine of the 90s. Critical Care Medicine
1999;27(1).
100.Mathieu-Nolf M Flumazenil use in an emergency department: a survey. J Toxical
Clin Toxical 2001;37(1):15-20.
101.Acetylcysteine. Mosby’s Drug consult 2002, Inc.
102.Nitroglycerin. Mosby’s Drug consult 2002, Inc.